Oxytocin and vasopressin stimulate anion secretion by human and porcine vas deferens epithelia.
Experiments were conducted to characterize the effects of oxytocin (OT) and vasopressin (VP) on epithelial cells isolated from human (1 degree HVD) and porcine (1 degree PVD) vas deferens and an immortalized epithelial cell line derived from porcine vas deferens (PVD9902 cells). Cultured monolayers were assessed in modified Ussing flux chambers and the OT- or VP-induced change in short circuit current (I(SC)) was recorded. All cell types responded to basolateral OT or VP with a transient increase in I(SC) that reached a peak of 3-5 microA cm(-2). Concentration-response curves constructed with 1 degree PVD and PVD9902 cells revealed that the apparent K(D) (k(app)) for OT was approximately 100-fold less than the k(app) for VP. Amplicons for the OT receptor (OXTR) and vasopressin type 2 and type 1a receptors (AVPR2 and AVPR1A) were generated with RT-PCR and the identification of each amplicon confirmed by sequence analysis. A selective antagonist for OXTR and AVPR1A fully blocked the effects of OT and partially blocked the effects of VP when assessed in both 1 degree PVD and PVD9902 monolayers. APVR2 antagonists blocked the effects of low (< or =30 nM) but not high concentrations of VP, indicating that VP was affecting both AVPR2 and a second receptor subtype, likely OXTR or AVPR1A. Experiments employing chelerythrine demonstrated that OT stimulation of vas deferens monolayers requires PKC activity. Alternatively, VP (but not OT) increased the accumulation of cytosolic cAMP in vas deferens epithelial cells. Results from this study demonstrate that OT and VP can modulate ion transport across vas deferens epithelia by independent mechanisms. OT and VP have the potential to acutely change the environment to which sperm are exposed and thus, have the potential to affect male fertility.
Hagedorn
Travis M
TM
Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506, USA.
Carlin
Ryan W
RW
Schultz
Bruce D
BD
D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D000838:Anions / Q000378:metabolism; D065092:Antidiuretic Hormone Receptor Antagonists; D053119:Benzophenanthridines / Q000494:pharmacology; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D004594:Electrophysiology; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D008297:Male; D010121:Oxytocin / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013552:Swine; D014649:Vas Deferens / Q000187:drug effects* / Q000378:metabolism*; D014667:Vasopressins / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000502:physiology
D000470:Alkaloids; D000838:Anions; D065092:Antidiuretic Hormone Receptor Antagonists; D053119:Benzophenanthridines; D010880:Piperidines; D015363:Quinolones; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D014667:Vasopressins; C068644:OPC 21268; D010121:Oxytocin; D000242:Cyclic AMP; C016299:chelerythrine